FOR U.S. HEALTHCARE PROFESSIONALS
ABBVIE MEDICAL AFFAIRS
The hepatitis C virus (HCV) landscape has changed
who is affected
types of providers
New cases of acute HCV have increased 375% since 20101
~44,300 estimated new cases of acute hepatitis C in 20171
CDC = Centers for Disease Control and Prevention
New infections increasing the most among 20- to 29-year-olds1
~8 out of 10 new HCV infections in 2014 in people who inject drugs (PWID)2
~2.3 million adults in the United States infected with HCV3
~50% unaware of infection4
There is good news
Today, interferon-free, all-oral DAA regimens offer short treatment durations and ...5
DAA = direct-acting antiviral
can cure* more than 95% of persons with HCV5,6
*Cure means the hep C virus is not detectable in the blood 3 months after treatment ends.7
2 out of 3 physicians believed patients did not have adequate access to providers in their community8
—According to a 2013 survey
Do we have enough providers needed to treat future patients?
Today’s regimens have been used effectively in nonspecialist settings, including in primary care.9,10
Expanding the treatment of HCV to nonspecialty settings helps reach and treat underserved populations:10,11
This expanded group of providers can include remote specialist oversight
allowing for more patients treated
and reduce specialist resource utilization12
The paradigm for treating HCV is shifting further—to non-MD clinical providers:13
The landscape has changed and comprehensive resources are needed sooner rather than later.
That’s why we developed HCV.com, with resources designed to help
Offering: Disease education
Offering: Treater resources
Offering: Discussion tools
The World Health Organization 2030 goal for HCV elimination is just 10 years away.14
At AbbVie, we believe that goal is achievable.
That’s why you’re here.
Welcome to HCV.com
1. Centers for Disease Control and Prevention. https://www.cdc.gov/hepatitis/statistics/2017surveillance/index.htm. Accessed September 25, 2019.
2. Zibbell JE, Asher AK, Patel RC, et al. Am J Public Health. 2018;108(2):175-181.
3. Rosenberg ES, Rosenthal EM, Hall EW, et al. JAMA Netw Open. 2018;1(8):e186371.
4. Yehia BR, Schranz AJ, Umscheid CA, Lo Re V III. PLoS ONE. 2014;9(7):e101554.
5. Lam BP, Jeffers T, Younoszai Z, Fazel Y, Younossi ZM. Therap Adv Gastroenterol. 2015;8(5):298-312.
6. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/hepatitis-c. Accessed September 25, 2019.
7. American Association for the Study of Liver Diseases/Infectious Diseases Society of America. https://www.hcvguidelines.org/evaluate/when-whom. Accessed September 25, 2019.
8. McGowan CE, Monis A, Bacon BR, et al. Hepatology. 2013;57(4):1325-1332.
9. Georgie F, Nafisi S, Kohli A, et al. J Hepatol. 2016;64(suppl 2):S818-S19.
10. Kattakuzhy S, Gross C, Emmanuel B, et al; ASCEND Providers. Ann Intern Med. 2017;167(5):311-318.
11. Beste LA, Glorioso TJ, Ho PM, et al. Am J Med. 2017;130(4):432-438.
12. Thomas J, Thompson H, Wu T, et al. Hepatology. 2018;68(suppl 1):465A-466A. Abstract 474.
13. Butt AA, Yan P, Lo Re V, Shaikh OS, Ross DB. Clin Infect Dis. 2019;68(5):857-859.
14. World Health Organization. https://www.who.int/hepatitis/publications/hep-elimination-by-2030-brief/en/. Accessed February 5, 2020.